ESOC 2023 | ESOC 2023 clinical trial highlights

The European Stroke Organisation Conference (ESOC) 2023 brought forth an exciting array of highlights for neurology professionals. Adnan Mujanovic, MD, PhD Candidate from Inselspital, Bern University Hospital, comments on some of the key data shared at the meeting. Regarding prevention, the ELAN trial (NCT03148457) tested the net benefit of early versus late initiation of direct oral anticoagulants in patients with an atrial fibrillation-related acute ischemic stroke, and ARCADIA (NCT03192215) examined apixaban versus aspirin in preventing recurrent stroke in atrial cardiopathy. The Phase III TIMELESS trial (NCT03785678) was also presented, which assessed the use of intravenous tenecteplase versus placebo in patients with acute ischemic stroke in the 4.5-24-hour time window. Dr Mujanovic also highlights the RESTORE trial: a rehabilitation study examining Ayuvedic rehabilitative treatment compared to conventional physiotherapy in improving sensorimotor recovery in patients with ischemic stroke. This interview took place during the European Stroke Organisation Conference (ESOC) in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.